0001576885-25-000011.txt : 20250107 0001576885-25-000011.hdr.sgml : 20250107 20250107195329 ACCESSION NUMBER: 0001576885-25-000011 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250103 FILED AS OF DATE: 20250107 DATE AS OF CHANGE: 20250107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zuga Matt CENTRAL INDEX KEY: 0001790214 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40551 FILM NUMBER: 25516246 MAIL ADDRESS: STREET 1: C/O TELA BIO, INC. STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001576885 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364108129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 BUSINESS PHONE: 925-368-8508 MAIL ADDRESS: STREET 1: 427 PARK ST. CITY: CHARLOTTESVILLE STATE: VA ZIP: 22902 4 1 wk-form4_1736297601.xml FORM 4 X0508 4 2025-01-03 0 0001576885 Acumen Pharmaceuticals, Inc. ABOS 0001790214 Zuga Matt C/O ACUMEN PHARMACEUTICALS, INC. 1210-1220 WASHINGTON STREET, SUITE 210 NEWTON MA 02465 0 1 0 0 CFO & Chief Business Officer 1 Common Stock 2025-01-03 4 S 0 13235 1.8411 D 198210 D Common Stock 2025-01-06 4 A 0 66800 0 A 265010 D Employee Stock Option (right to buy) 1.85 2025-01-06 4 A 0 100300 0 A 2035-01-06 Common Stock 100300 100300 D Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2024. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7700 to $1.9000. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents an RSU award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date. /s/ Derek Meisner, Attorney-in-Fact 2025-01-07